Despite a growing number of approved monoclonal antibodies targeting respiratory diseases, none are delivered by inhalation. All are administered systemically, restricting access to the most severe patients and requiring high doses with significant side effects. Inhalation could unlock lower doses and broader patient populations – but nebulization damages antibodies, and no validated solution currently exists.

SoteriaBio is a French pre-clinical stage biotech company developing a proprietary technology platform enabling the inhaled delivery of monoclonal antibodies for respiratory diseases. Backed $4M in equity seed funding and grants, SoteriaBio has demonstrated in vivo proof of concept showing complete lung distribution, significantly higher local concentration versus systemic injection, and therapeutic efficacy in preclinical asthma and COVID models.

SoteriaBio is actively seeking partnerships with companies developing or commercializing monoclonal antibodies for respiratory diseases, as well as opportunities to build its own inhaled biologic pipeline.

Originating from MedXCell SA (a Swiss Venture Builder) and academic collaborations with EPFL and ICGM/CNRS, SoteriaBio is led by Anh Nguyen, founder of MedinCell (EURONEXT: MEDCL). The company operates in Montpellier (France) and Montreux (Switzerland).